Ganetespib has helped a leukemia patient in the past. (This is from 2010!)
New drug stops leukemia cell development
The drug, STA-9090, is currently under development by Synta Pharmaceuticals Corp. Although the drug must undergo more clinical trials, in the Phase I study CTRC researchers were able to show that the drug interferes with the heat shock protein’s ability to help WT1, stopping leukemia cell development and effectively killing the cell. Researchers were also able to show a new discovery: that WT1 interacts with a particular heat shock protein, HSP90.
Ultimately, the experimental drug helped Rodriguez survive during her wait for a bone marrow donor, and helped researchers better understand how to treat the bone marrow cancer by fighting the mechanisms that allow it to grow. That may help define novel therapeutic strategies in the future.